AU2002226060A1 - Compositions containing gangliosides for use in the treatment of skin disorders - Google Patents

Compositions containing gangliosides for use in the treatment of skin disorders

Info

Publication number
AU2002226060A1
AU2002226060A1 AU2002226060A AU2606002A AU2002226060A1 AU 2002226060 A1 AU2002226060 A1 AU 2002226060A1 AU 2002226060 A AU2002226060 A AU 2002226060A AU 2606002 A AU2606002 A AU 2606002A AU 2002226060 A1 AU2002226060 A1 AU 2002226060A1
Authority
AU
Australia
Prior art keywords
treatment
compositions containing
skin disorders
containing gangliosides
gangliosides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002226060A
Inventor
Amy S. Paller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Memorial Hospital
Original Assignee
Childrens Memorial Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Memorial Hospital filed Critical Childrens Memorial Hospital
Publication of AU2002226060A1 publication Critical patent/AU2002226060A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2002226060A 2000-12-08 2001-12-07 Compositions containing gangliosides for use in the treatment of skin disorders Abandoned AU2002226060A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25438700P 2000-12-08 2000-12-08
US60254387 2000-12-08
US10/013,788 US20020122795A1 (en) 2000-12-08 2001-12-07 Compositions containing gangliosides for use in the treatment of skin disorders
PCT/US2001/047551 WO2002045740A1 (en) 2000-12-08 2001-12-07 Compositions containing gangliosides for use in the treatment of skin disorders
US10013788 2001-12-07

Publications (1)

Publication Number Publication Date
AU2002226060A1 true AU2002226060A1 (en) 2002-06-18

Family

ID=26685246

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002226060A Abandoned AU2002226060A1 (en) 2000-12-08 2001-12-07 Compositions containing gangliosides for use in the treatment of skin disorders

Country Status (7)

Country Link
US (1) US20020122795A1 (en)
EP (1) EP1349567A4 (en)
JP (1) JP2004531469A (en)
AU (1) AU2002226060A1 (en)
GB (1) GB2388777A (en)
IL (1) IL156045A0 (en)
WO (1) WO2002045740A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6998392B2 (en) * 2003-04-02 2006-02-14 Mti Meta Tech Inc. Formulation to treat or prevent parasitic infection
US8536140B2 (en) 2004-03-12 2013-09-17 Mti Meta Tech Inc. Methods for treating inflammatory bowel disease
US7851451B2 (en) 2004-03-12 2010-12-14 Mti Meta Tech Inc. Formulations for mediating inflammatory bowel disorders
EP1797898A4 (en) * 2004-09-08 2009-09-09 Takeda Pharmaceutical Preventive/therapeutic drug for arteriosclerosis
JP2008214241A (en) * 2007-03-02 2008-09-18 Snow Brand Milk Prod Co Ltd Immunomodulator
JP5596444B2 (en) * 2010-07-07 2014-09-24 花王株式会社 Method for evaluating or selecting anti-inflammatory agent
US20130040953A1 (en) * 2011-08-10 2013-02-14 Amy S. Paller Promotion of wound healing
US9655967B2 (en) * 2011-12-09 2017-05-23 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of focal adhesion kinase for control of scar tissue formation
US20230233437A1 (en) * 2020-05-25 2023-07-27 Shizuoka Prefectural University Corporation Elastin production promoter and cosmetic preparation for skin

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA833446B (en) * 1982-05-28 1984-02-29 Solco Basel Ag Process for the preparation of cell-and tissue-regenerating substances
IT1177863B (en) * 1984-07-03 1987-08-26 Fidia Farmaceutici A GANGLIOSIDIC MIXTURE AS A THERAPEUTIC AGENT TO ELIMINATE PAIN IN PERIPHERAL NEUROPATHIES
US4767746A (en) * 1985-12-04 1988-08-30 Trustees Of Boston University Method for enhancement of healing of epithelial wounds in mammals
GB8620361D0 (en) * 1986-08-21 1986-10-01 Windleshaw Enterprises Ltd Pharmaceutical compositions
US4816450A (en) * 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US5272138A (en) * 1988-02-12 1993-12-21 The Biomembrane Institute Naturally occurring gangliosides containing de-N-acetyl-sialic acid and their applications as modifiers of cell physiology
US5102663A (en) * 1988-10-18 1992-04-07 Sloan-Kettering Instutute For Cancer Research Vaccine for stimulating or enhancing production of antibodies against 9-O-acetyl GD3
US5840317A (en) * 1989-11-03 1998-11-24 Morton; Donald L. Composition comprising tumor cell lines containing GD2 ganglioside GM2 ganglioside, M-TAA, and either M-urinary antigen or M-fetal antigen
DE4107154A1 (en) * 1990-10-11 1992-04-16 Boehringer Mannheim Gmbh MONOCLONAL ANTICOERPER AGAINST MELANOMA
US5208146A (en) * 1990-11-05 1993-05-04 The Regents Of The University Of California Murine monoclonal anti-idiotype antibodies
WO1993002686A1 (en) * 1991-07-31 1993-02-18 The Regents Of The University Of California Gangliosides with immunosuppressive ceramide moieties
WO1993010221A1 (en) * 1991-11-13 1993-05-27 The Regents Of The University Of California Chimeric murine/human anti-idiotype monoclonal antibodies
DE4208795A1 (en) * 1992-03-19 1993-09-23 Behringwerke Ag MONOCLONAL ANTI-GANGLIOSIDE ANTIBODY, ITS PRODUCTION AND USE AS A TUMOR THERAPEUTIC
BR9306564A (en) * 1992-06-19 1999-01-12 Univ California Process for the treatment of the epidermis of a terrestrial mammal suffering from a condition consisting of a disturbed epidermal barrier function
EP0666268B1 (en) * 1992-10-22 2000-04-19 Kirin Beer Kabushiki Kaisha Novel sphingoglycolipid and use thereof
JP3141693B2 (en) * 1994-08-16 2001-03-05 ダイキン工業株式会社 Ganglioside GM3 analogs in which 9-position of sialic acid is substituted by fluorine and intermediates thereof
US6054433A (en) * 1994-11-03 2000-04-25 The Regents Of The University Of California Methods and compositions for stimulating tissue growth and epithelial moisturization
US5977316A (en) * 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
CA2227013A1 (en) * 1995-07-14 1997-02-06 Glycotech Corp. Compounds and methods for treatment of egf receptor associated cancers and purification of the egf receptor
US5690966A (en) * 1996-10-17 1997-11-25 Council Of Scientific & Industrial Research Process for the preparation of an extract from human placenta containing glycosphingolipids and endothelin-like constituent peptides useful for the treatment of vitiligo
WO1998039027A2 (en) * 1997-03-05 1998-09-11 John Wayne Cancer Institute Sialyl lewis antigens as targets for immunotherapy
CU22731A1 (en) * 1998-02-05 2002-02-28 Centro Inmunologia Molecular MONOCLONAL ANTIBODY THAT RECOGNIZES THE SYNLICAL OLIGOSACÁRIDO SYNALIC N´GLICOLILADO-GALACTOSA-GLUCOSA (NGCNEU-GAL-GLU) IN MALIGN TUMORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Also Published As

Publication number Publication date
US20020122795A1 (en) 2002-09-05
IL156045A0 (en) 2003-12-23
GB2388777A (en) 2003-11-26
EP1349567A1 (en) 2003-10-08
GB0316026D0 (en) 2003-08-13
JP2004531469A (en) 2004-10-14
WO2002045740A1 (en) 2002-06-13
EP1349567A4 (en) 2005-10-12

Similar Documents

Publication Publication Date Title
AU2001271973A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2001278852A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
IL127943A (en) Pharmaceutical and cosmetic compositions for the treatment of skin disorders
AU2001266152A1 (en) Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
HUP0104963A3 (en) Compositions for the treatment of skin diseases
AU2002226060A1 (en) Compositions containing gangliosides for use in the treatment of skin disorders
AU5056099A (en) Compounds for use in the treatment of inflammation
AU4789099A (en) Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents
AU7106300A (en) Treatment of skin disorders
HUP0204391A3 (en) The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders
AU2002352566A1 (en) Use of corrinoids in the treatment of skin diseases
GB2354944B (en) Skin treatment compositions
AU2001283199A1 (en) Methods and compositions for the diagnosis and treatment of brown adipose cell disorders
AU2002210763A1 (en) Use of 1-ebio in the treatment of bipolar disorders
IL150527A0 (en) Use of vitamin d-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives
AU1022501A (en) Use of compositions for the caring treatment of the skin
AU3061199A (en) Skin treatment compositions and the use thereof
GB9904252D0 (en) Composition for the treatment of pain
AU2002348324A1 (en) Methods and compositions for the treatment and diagnosis of pain disorders using 46566
AU6106599A (en) Device for use in treatment of hair
AU747073C (en) Utilization of derivatives of tetrahydropyridines (or 4-hydroxypiperidines)-butylazols in the preparation of medicament for the treatment of pain
AU2002357691A1 (en) Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145
AU2001274446A1 (en) Vip-related peptides for the treatment of skin disorders
AU2256801A (en) Methods and compositions for use in the treatment of filovirus mediated disease conditions
AU2002360318A1 (en) Methods and compositions for the treatment and diagnosis of pain disorders using 9805